Chemical Information | |
Antiviral agent ID | DrugRepV_7118 | |
Antiviral agent name | 4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide | |
IUPAC Name | 4-[3-(4-fluorophenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide | |
SMILES (canonical) | C1C(N(N=C1C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N)C4=CC=C(C=C4)F | |
Molecular Formula | C21H18FN3O2S | |
Molecular Weight (g/mol) | 395.452 | |
InChl | InChI=1S/C21H18FN3O2S/c22-17-8-6-16(7-9-17)21-14-20(15-4-2-1-3-5-15)24-25(21)18-10-12-19(13-11-18)28(23,26)27/h1-13,21H,14H2,(H2,23,26,27) | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Secondary Indication | Yellow fever virus (YFV) NA 17D | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | BHK-21
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 0.01 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Drug concentration) | 2.6 ± 0.4 μM
| |
Secondary Indication (Cell based assay) | MTT assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | EC50 [ 50 % ] | |
Secondary Indication (Cytotoxicity) | 13 ± 2 μM | |
Reference | Fioravanti R, Desideri N, Carta A, Atzori EM, Delogu I, Collu G, Loddo R..Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation..Eur J Med Chem. 2017 Dec 1;141:15-25. doi: 10.1016/j.ejmech.2017.09.060. Epub 2017 Sep 28. PMID:29028528
| |
Comment | 6-Azauridine, ribavirin, 2'-C-methyl-guanosin (NM108), efavirenz (EFV), pleconaril, acyclovir (ACG), and mycophenolic acid (M5255) were employed as reference inhibitors.
| |